Literature DB >> 20117083

Identification of a small-molecule inhibitor of the interaction between Survivin and Smac/DIABLO.

Tsuyoshi Oikawa1, Yuka Unno, Kenji Matsuno, Jun-ichi Sawada, Naohisa Ogo, Kiyoshi Tanaka, Akira Asai.   

Abstract

The protein Survivin is selectively overexpressed in a variety of cancers, but not in normal tissues. It has been reported to be involved in cell survival and cell division. However, the molecular mechanisms involved in its function are not clear, although several binding partner proteins have been proposed to date. Here, we report the identification of a novel small molecule Survivin antagonist, which disrupts the Survivin-Smac/DIABLO interaction in cells. In order to identify Survivin-directed antagonists, we developed a high-throughput screening system based on AlphaScreen technology, which allows the identification of small molecules with the ability to inhibit the interaction of Survivin with Smac/DIABLO or INCENP in vitro. We screened chemical libraries, generated in-house, using this system and identified a 5-deazaflavin analog (compound 1) as a hit compound that selectively inhibited the interaction of Survivin with Smac/DIABLO but not INCENP. In cultured cells, compound 1 abrogated the formation of the complex between Survivin and Smac/DIABLO. In addition, this compound was able to sensitize cultured cells to doxorubicin-mediated DNA damage stress and synergistically enhance apoptotic cell death. Thus, the small-molecule inhibitor described here may serve as a proof-of-principle agent for discriminating between the multiple functions of Survivin. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117083     DOI: 10.1016/j.bbrc.2010.01.113

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

Authors:  Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson
Journal:  Int J Biochem Cell Biol       Date:  2011-10-25       Impact factor: 5.085

2.  Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.

Authors:  Astrid Weiss; Boris Brill; Corina Borghouts; Natalia Delis; Laura Mack; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

Review 3.  Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.

Authors:  Bernd Groner; Axel Weber; Laura Mack
Journal:  Bioengineered       Date:  2012-07-24       Impact factor: 3.269

4.  Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts.

Authors:  Thomas H Sisson; Toby M Maher; Iyabode O Ajayi; Jessie E King; Peter D R Higgins; Adam J Booth; Rommel L Sagana; Steven K Huang; Eric S White; Bethany B Moore; Jeffrey C Horowitz
Journal:  Adv Biosci Biotechnol       Date:  2012-10

5.  Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides.

Authors:  Timothy J Bergmann; Ilaria Fregno; Fiorenza Fumagalli; Andrea Rinaldi; Francesco Bertoni; Paul J Boersema; Paola Picotti; Maurizio Molinari
Journal:  J Biol Chem       Date:  2018-02-16       Impact factor: 5.157

6.  Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells.

Authors:  Ragini Jenkins; Yuriy P Bandera; Michael A Daniele; LeAnna L Ledford; Ashlee Tietje; Andrew A Kelso; Michael G Sehorn; Yanzhang Wei; Mrinmay Chakrabarti; Swapan K Ray; Stephen H Foulger
Journal:  Biomater Sci       Date:  2016-02-04       Impact factor: 6.843

7.  A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells.

Authors:  Corina Borghouts; Natalia Delis; Boris Brill; Astrid Weiss; Laura Mack; Peter Lucks; Bernd Groner
Journal:  JAKSTAT       Date:  2012-01-01

Review 8.  Targeting survivin in cancer: novel drug development approaches.

Authors:  Bernd Groner; Astrid Weiss
Journal:  BioDrugs       Date:  2014-02       Impact factor: 5.807

Review 9.  Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.

Authors:  Zakir Khan; Abdul Arif Khan; Hariom Yadav; Godavarthi B K S Prasad; Prakash Singh Bisen
Journal:  Cell Mol Biol Lett       Date:  2017-04-05       Impact factor: 5.787

10.  Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.

Authors:  Kazuyuki Takakuma; Naohisa Ogo; Yutaka Uehara; Susumu Takahashi; Nao Miyoshi; Akira Asai
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.